NCT03959553View on ClinicalTrials.gov

GV1001 Subcutaneous(SC) for the Treatment of Moderate Alzheimer's Disease (AD)

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

September 1, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

February 28, 2022

Conditions

Moderate Alzheimer's Disease

Interventions

DRUG

GV1001

Lyophilized peptide from hTERT

DRUG

Normal saline

0.9% normal saline

Sponsors

Lead Sponsor

All Listed Sponsors

lead

GemVax & Kael

INDUSTRY